India is getting ready to roll out BPaL (bedaquiline, pretomanid, and linezolid) regimen for all multi/extensively drug-resistant tuberculosis patients.
- This is a significant move in the country’s battle against with the new regime indicating good results in countries including Pakistan, South Africa, Ukraine, etc.
- The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and difficult challenges facing global TB control.
Multidrug-resistant (MDR) TB: Patients who are infected with strains resistant to isoniazid and rifampicin, called multidrug-resistant (MDR) TB, are practically incurable by standard first-line treatment.
Extensively drug-resistant (XDR) TB: It refers to MDR-TB strains that are resistant to fluoroquinolones and second-line injectable drugs.
Causes:
The main causes of the spread of resistant TB are weak medical systems, amplification of resistance patterns through incorrect treatment, and transmission in communities and facilities. |
What is BPaL?
- BPaL is a new all-oral combination of drugs consisting of Bedaquiline (B), Pretomanid (Pa) and Linezolid (L).
- The new regimen is also expected to be more cost-effective, reducing treatment costs significantly.
Enroll now for UPSC Online Classes
Significance
- Cost Effective: “After the availability of generic bedaquiline cost to TB programmes has fallen – (BPaLM price is US$426 (US$130 bedaquiline, US$238 pretomanid, US$31 linezolid and US$27 moxifloxacin).
- Enhance Treatment Outcomes: The regimen shortens treatment duration from 18-24 months to about six months and simplifies the process to three daily tablets, compared to the previous regimen of 14 drugs.
- Increase Adherences treatment: A shorter regimen, such as BPaL, which is all oral and requires lesser doses per day, will make it easier for a patient to adhere to and complete treatments,
Impact on Treatment
- Currently, India’s success rate for MDR/RR-TB is 56%, and 48% for XDR-TB.
- The BPaL regimen, endorsed by the WHO, aims to improve these rates by offering a shorter, less toxic treatment.
- According to a recent study, the BPaL/BPaLM regimens have been proven to be more effective, affordable, and less burdensome for patients.
Elimination Strategy
Although patients harbouring MDR and XDR strains present a formidable challenge for treatment, cure is often possible with early identification of resistance and use of a properly designed regimen.
- Scaling up NAAT (diagnosis) coverage will be an essential element of the strategy.
- Community-based programs can improve treatment outcomes by allowing patients to be treated in their homes and addressing socioeconomic barriers to adherence.
Check Out UPSC NCERT Textbooks From PW Store
A nucleic acid amplification test, or NAAT, for tuberculosis (TB) is a molecular test used to detect the DNA (deoxyribonucleic acid) of Mycobacterium tuberculosis complex (MTBC) in a sputum or other respiratory sample. |